Zhiwen Fu
YOU?
Author Swipe
View article: The post-marketing safety of Esketamine among older adults(≥ 65): an real-world pharmacovigilance study
The post-marketing safety of Esketamine among older adults(≥ 65): an real-world pharmacovigilance study Open
Aims This study aims to investigate the safety profile of Esketamine, with a particular focus on comparing adverse events (AEs) between adults (< 65 years) and older adults (≥ 65 years) using data from the FDA Adverse Event Reporting Syste…
View article: Antifungal activity and inhibitory mechanism of essential oil from fresh and fallen leaves of Cinnamomum camphora (L.) presl against zearalenone-producing Fusarium graminearum
Antifungal activity and inhibitory mechanism of essential oil from fresh and fallen leaves of Cinnamomum camphora (L.) presl against zearalenone-producing Fusarium graminearum Open
View article: Safety profile and dose-dependent adverse events of upadacitinib in randomized clinical trials: a systematic review and meta-analysis
Safety profile and dose-dependent adverse events of upadacitinib in randomized clinical trials: a systematic review and meta-analysis Open
Introduction Upadacitinib, one of the Janus kinase (JAK) inhibitors, has gained global approval for treating various inflammatory and autoimmune diseases. However, despite the FDA’s black box warning on all JAK inhibitors, further research…
View article: Personalized prediction of gait freezing using dynamic mode decomposition
Personalized prediction of gait freezing using dynamic mode decomposition Open
View article: Disproportionality Analysis of Renal Adverse Events Associated with a Combination of Immune Checkpoint Inhibitors and Acid-Suppressing Agents—A Pharmacovigilance Study Based on the FAERS Database
Disproportionality Analysis of Renal Adverse Events Associated with a Combination of Immune Checkpoint Inhibitors and Acid-Suppressing Agents—A Pharmacovigilance Study Based on the FAERS Database Open
Background/Objectives: The nephrotoxicity of immune checkpoint inhibitors (ICIs) combined with proton pump inhibitors (PPIs) has been recognized but lacks a comprehensive analysis. We conducted an in-depth investigation of renal adverse ev…
View article: QingGan LiDan capsules improved alcoholic liver injury by regulating liver lipid transport and oxidative stress in mice
QingGan LiDan capsules improved alcoholic liver injury by regulating liver lipid transport and oxidative stress in mice Open
Background The QingGan LiDan capsule (QGLD) consists of five traditional Chinese herbs, which have been used for hepatobiliary diseases such as jaundice. However, the effects and mechanisms by which QGLD prevent alcoholic liver diseases (A…
View article: The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database
The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database Open
The clinically observed AEs, along with potential new AE signals associated with empagliflozin were identified based on the FAERS database, which could provide valuable evidence for clinical monitoring, risk identification, and further saf…
View article: Musculoskeletal adverse events associated with CDK4/6 inhibitors: a real-world study using FDA Adverse Event Reporting System (FAERS) database
Musculoskeletal adverse events associated with CDK4/6 inhibitors: a real-world study using FDA Adverse Event Reporting System (FAERS) database Open
View article: Personalized Prediction of Gait Freezing Using Dynamic Mode Decomposition
Personalized Prediction of Gait Freezing Using Dynamic Mode Decomposition Open
Freezing of gait (FOG) is a common severe gait disorder in patients with advanced Parkinson's disease (PD). The ability to predict the onset of FOG episodes early on allows for timely intervention, which is essential for improving the life…
View article: Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery Open
View article: AKR1C1 interacts with STAT3 to increase intracellular glutathione and confers resistance to oxaliplatin in colorectal cancer
AKR1C1 interacts with STAT3 to increase intracellular glutathione and confers resistance to oxaliplatin in colorectal cancer Open
View article: Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database
Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database Open
Background: Bevacizumab (BV) is widely used in routine cancer treatment and clinical therapy in combination with many other agents. This study aims to describe and analyse post-market cases of pulmonary haemorrhage and haemoptysis reported…
View article: Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database
Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database Open
Background: Immune checkpoint inhibitors (ICIs), including anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies, have become a standard treatment for multiple cancer types. However, ICIs can induce immune-related adverse events, with hepatitis…
View article: Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database
Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database Open
Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used due to their profound efficacy in glycemic control and weight management. Within real-world contexts, the manifestation of certain psychiatric adverse events …
View article: Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway
Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway Open
Almonertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (…
View article: Correction: Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy
Correction: Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy Open
View article: Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials
Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials Open
View article: Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy
Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy Open
View article: Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates
Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates Open
Since the successful approval of gemtuzumab ozogamicin, antibody-drug conjugates (ADCs) have emerged as a pivotal category of targeted therapies for cancer. Among these ADCs, the use of monomethyl auristatin E (MMAE) as a payload is preval…
View article: Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system
Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system Open
We analyze and identify the signals of gender differences in adverse events (ADEs) related to Osimertinib and provide reference for clinical implementation of individualized drug use. ADE reports of Osimertinib received from FAERS database…
View article: Corrigendum to “Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis” [EClinicalMedicine 55 (2022) 101795]
Corrigendum to “Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis” [EClinicalMedicine 55 (2022) 101795] Open
[This corrects the article DOI: 10.1016/j.eclinm.2023.101904.][This corrects the article DOI: 10.1016/j.eclinm.2022.101795.].
View article: Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations Open
View article: Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system
Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system Open
Guselkumab is an IL−23 inhibitor widely used for the treatment of moderate-to-severe plaque psoriasis. Our study aimed to characterize the profile of adverse events (AEs) associated with guselkumab from the FDA adverse event reporting syst…
View article: Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis
Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis Open
The National Natural Science Foundation of China (Grant No. 82073402) and Key R&D Plan of Hubei Province, China (No.2020BCA060) funded this study.
View article: Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Antibody drug conjugate: the “biological missile” for targeted cancer therapy Open
View article: Natural Product Alantolactone Targeting AKR1C1 Suppresses Cell Proliferation and Metastasis in Non-Small-Cell Lung Cancer
Natural Product Alantolactone Targeting AKR1C1 Suppresses Cell Proliferation and Metastasis in Non-Small-Cell Lung Cancer Open
Non-small-cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths, characterized by high invasion and metastasis. Aldo-keto reductase family 1 member C1 (AKR1C1) plays an important role in cancer cell proliferation a…
View article: MicroRNA as an Important Target for Anticancer Drug Development
MicroRNA as an Important Target for Anticancer Drug Development Open
Cancer has become the second greatest cause of death worldwide. Although there are several different classes of anticancer drugs that are available in clinic, some tough issues like side-effects and low efficacy still need to dissolve. The…
View article: Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in mice
Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in mice Open